The Relationship between Galectin-3 and Different Patterns of Ventricular Geometry Remodelling in Aortic Valve Stenosis

Heart Lung and Circulation

Volumn 25, Issue 4, 2016, Pages 371-377

  Zhou, Kang ^a   Zhou, Yangzhao ^a   Zhao, Yuan ^a   Tan, Changming ^a   Yuan, Zhaoshun ^a   Li, Jianming ^a   Liao, Xiaobo ^a   Gu, Lu ^a   Zhou, Xinmin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Aortic stenosis; Fibrosis; Galectin 3; Myocardial hypertrophy; Myocardial remodelling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; BRAIN NATRIURETIC PEPTIDE; GALECTIN-3, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTERIAL WALL THICKNESS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; HEART LEFT VENTRICLE MASS; HEART VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; VENTRICULAR GEOMETRY REMODELLING; BLOOD; CLINICAL TRIAL; HEART VENTRICLE REMODELING; MIDDLE AGED; PATHOLOGY;

ADULT; AORTIC VALVE STENOSIS; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; VENTRICULAR REMODELING;

EID: 84959018066     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2015.08.021     Document Type: Article

References (28)

1. Ganau A., Devereux R.B., Roman M.J., de Simone G., Pickering T.G., Saba P.S., et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992, 19:1550-1558.
2. Yarbrough W.M., Mukherjee R., Ikonomidis J.S., Zile M.R., Spinale F.G. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012, 143:656-664.
3. Hein S., Arnon E., Kostin S., Schonburg M., Elsasser A., Polyakova V., et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 2003, 107:984-991.
4. Weidemann F., Herrmann S., Stork S., Niemann M., Frantz S., Lange V., et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation. 2009, 120:577-584.
5. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999, 79:215-262.
6. Henderson N.C., Mackinnon A.C., Farnworth S.L., Kipari T., Haslett C., Iredale J.P., et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008, 172:288-298.
7. Bosnjak I., Selthofer-Relatic K., Vcev A. Prognostic value of galectin-3 in patients with heart failure. Dis Markers. 2015, 2015:1-6.
8. Jagodzinski A., Havulinna A.S., Appelbaum S., Zeller T., Jousilahti P., Skytte-Johanssen S., et al. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Int J Cardiol. 2015, 192:33-39.
9. Sharma U.C., Pokharel S., van Brakel T.J., van Berlo J.H., Cleutjens J.P., Schroen B., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004, 110:3121-3128.
10. Morrow D.A., O'Donoghue M.L. Galectin-3 in cardiovascular disease: a possible window into early myocardial fibrosis. J Am Coll Cardiol. 2012, 60:1257-1258.
11. Lok D.J., Van Der Meer P., de la Porte P.W., Lipsic E., Van Wijngaarden J., Hillege H.L., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010, 99:323-328.
12. Nishimura R.A., Otto C.M., Bonow R.O., Carabello B.A., Erwin J.P., Guyton R.A., et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014, 129:e521-e643.
13. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005, 18:1440-1463.
14. Ghanem A., Roll W., Hashemi T., Dewald O., Djoufack P.C., Fink K.B., et al. Echocardiographic assessment of left ventricular mass in neonatal and adult mice: accuracy of different echocardiographic methods. Echocardiography. 2006, 23:900-907.
15. Golia G., Milano A.D., Dodonov M., Bergamini C., Faggian G., Tomezzoli A., et al. Influence of myocardial fibrosis on left ventricular hypertrophy in patients with symptomatic severe aortic stenosis. Cardiology. 2011, 120:139-145.
16. Smilde T.D., van Veldhuisen D.J., Navis G., Voors A.A., Hillege H.L. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation. 2006, 114:1572-1580.
17. Gaasch W.H., Zile M.R. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol. 2011, 58:1733-1740.
18. Rieck A.E., Cramariuc D., Boman K., Gohlke-Barwolf C., Staal E.M., Lonnebakken M.T., et al. Hypertension in aortic stenosis: implications for left ventricular structure and cardiovascular events. Hypertension. 2012, 60:90-97.
19. Meijers W.C., van der Velde A.R., Pascual-Figal D.A., de Boer R.A. Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol. 2015, (Epub ahead of print).
20. Pacileo G., Calabro P., Limongelli G., Russo M.G., Pisacane C., Sarubbi B., et al. Left ventricular remodeling, mechanics, and tissue characterization in congenital aortic stenosis. J Am Soc Echocardiogr. 2003, 16:214-220.
21. Verdecchia P., Angeli F., Achilli P., Castellani C., Broccatelli A., Gattobigio R., et al. Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events. Curr Opin Cardiol. 2007, 22:329-334.
22. de Boer R.A., Yu L., van Veldhuisen D.J. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010, 7(1):1-8.
23. Baldenhofer G., Zhang K., Spethmann S., Laule M., Eilers B., Leonhardt F., et al. Galectin-3 predicts short- and long-term outcome in patients undergoing transcatheter aortic valve implantation (TAVI). Int J Cardiol. 2014, 177:912-917.
24. Lin Y.H., Lin L.Y., Wu Y.W., Chien K.L., Lee C.M., Hsu R.B., et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta. 2009, 409:96-99.
25. Azevedo C.F., Nigri M., Higuchi M.L., Pomerantzeff P.M., Spina G.S., Sampaio R.O., et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol. 2010, 56:278-287.
26. Lindman B.R., AUID- Oho, Breyley J.G., Schilling J.D., Vatterott A.M., Zajarias A., et al. Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. Heart. 2015, (Epub ahead of print).
27. Ambrosi P., Oddoze C., Habib G. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002, 106:e70.
28. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., Sharma U.C., Bakker J.A., Low A.F., Martinez A., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006, 48:1217-1224.